Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- MHLW Panel to Elaborate Proposed Scheme to Broaden Drug Development Requests
July 15, 2014
- Editor’s Pick: Five Healthcare News Headlines for June 30 - July 11
July 14, 2014
- Revised PAL to Go Live on November 25: Ministry Exec
July 14, 2014
- Science Ministry’s Updated Guidelines to Require Research Data Preservation
July 14, 2014
- Draft Policy on Resource Allocation Focuses Funding on 9 Fields of Healthcare R&D
July 14, 2014
- Is Legal Regulation Necessary? Clinical Research at Turning Point 1: TRI Director Fukushima
July 14, 2014
- Unami Tapped as New Budget Examiner for Health Finances
July 11, 2014
- PFSB Announces Final Draft of Drug Interaction Guidelines
July 11, 2014
- Utsunomiya to Move to National Center for Global Health and Medicine
July 10, 2014
- MHLW Orders Revisions of Precaution Statements for a Number of Drugs Including Forteo and Paxil
July 10, 2014
- MHLW Releases Report on Medical Database Project
July 9, 2014
- Doctors at Ryukaikon Council Request Mandatory Inclusion of Expiry Dates in Product Barcodes
July 8, 2014
- MHLW OKs IFN-Free Hepatitis C Treatments
July 8, 2014
- Keiya Iida of METI to Be First “Councilor for the Promotion of Pharmaceutical and Related Industries”: MHLW
July 8, 2014
- Kiyohito Nakai to Be Appointed Pharmaceutical Management Director
July 8, 2014
- Ryukaikon Council Member Requests Rewards instead of Penalties for Early Delivery Price Settlements
July 7, 2014
- Initiatives for Drug Distribution Improvement Advanced in FY2013: Ryukaikon Council
July 7, 2014
- Yuji Kanda to Head PFSB, Kazuo Futagawa to Head HPB Following Reshuffling of MHLW Top Officials
July 7, 2014
- MHLW to Issue Business Practice Improvement Order to Novartis for Violation of ADR Reporting Requirement
July 4, 2014
- MHLW to Require RMP Submissions around August for Generics of Blue Letter-Issued Original Drugs
July 2, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…